CAG
NVAX icon

Csenge Advisory Group’s Novavax NVAX Stock Holding History

Csenge Advisory Group’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,482
Closed -$231K – 639
2022
Q2 		$231K Buy
4,482
+1,100
+33% +$57K 0.02% 508
2022
Q1 		$249K Buy
3,382
+930
+38% +$82.9K 0.02% 545
2021
Q4 		$529K Sell
2,452
-1,195
-33% -$205K 0.05% 331
2021
Q3 		$662K Buy
3,647
+1,195
+49% +$263K 0.06% 303
2021
Q2 		$529K Hold
2,452
– – 0.05% 332
2021
Q1 		$441K Buy
2,452
+302
+14% +$60.2K 0.05% 305
2020
Q4 		$240K Hold
2,150
– – 0.03% 373
2020
Q3 		$231K Buy
+2,150
New +$262K 0.03% 354
2018
Q4 		– Sell
-25
Closed – – 1053
2018
Q3 		$0 Buy
+25
New +$704 ﹤0.01% 1421

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Csenge Advisory Group's NVAX Position: Q3 2022 in Review

Csenge Advisory Group sold out of Novavax (NVAX) in Q3 2022, closing a stake of 4,482 shares — an estimated $231K sold.

Csenge Advisory Group first reported a position in NVAX in Q3 2018 and held it in 9 quarters. The position peaked at $662K in Q3 2021. 253 funds tracked by Wall St. Rank hold NVAX as of Q3 2022.

  • Csenge Advisory Group reported no remaining Novavax position as of Q3 2022 after selling out during the quarter.
  • Csenge Advisory Group sold 4,482 Novavax shares in Q3 2022, an estimated $231K.
  • Csenge Advisory Group first reported a position in Novavax in Q3 2018 and held it in 9 quarters.
  • Csenge Advisory Group's Novavax position peaked at $662K in Q3 2021.
  • 253 funds tracked by Wall St. Rank held Novavax as of Q3 2022.

Based on Csenge Advisory Group's 13F filing for Q3 2022, filed 4 Oct 2022.